Note: Descriptions are shown in the official language in which they were submitted.
~,J ~ 3
TITLE OF THE INVENTION
SUSTAINED~RELEASE PRANOPROFEN PREPARATION
BACKGROVND OF THE INVENTION
Field of the Invention:
The present invention relates to a sustained-release
pranoprofen preparation useful as an antipyretic, analgesic,
or anti-inflammatory drug.
Description of the Back~round:
Among non-steroidal anti-inflammakory drugs, propionic
acid compounds typified by pranoprofen, ketoprofen, and
ibuprofen exhibit excellently balanced antipyretic and
anti-inflammatory effects with less side effects than other
non-steroidal anti-inflammatory drugs. These drug~ thus are
widely used as a first drug of choice in clinics.
Especially, pranoprofen is a superior anti-inflammatory drug
with a minimal risk of side effects on gastrointestinal
tract, which is common to non~steroidal anti-inflammatory
drugs due to their special phaxmaceutical actions.
A defect of pr~noprofen i~ its short half-life period
in blood, requiring the patients to dose the drug 3 times a
day, which the patients sometimes feel difficulty to comply
with. This is undesirable from the aspect of controlling
diseases. Even if its side effect is small, a rapid
concentration increase of a drug in blood after oral
administration is by not necessarily means safe for
patients. ~evelopment of a pranoprofen preparation which
can safely deliver the effect6 of pranoprofen over a long
` :. .............. '
~, ' .
' ' `` . '
.
",
L ~' J ~, ~
period of time is therefore desired.
In view of this situation, the pre~ent inventors have
undertaken extensive studies and found that the use of an
oily component, water-soluble component, water-insoluble
component, or intestinally soluble component, as sustained-
release components, can effectively control the rate of
release of pranoprofen. This finding has led to the
completion of the present invention.
SUM~RY OF THE INVENTION
Accordingly, an ob~ect of the present invention is to
provide a sustained-release pranopro~en preparation
comprising an effective amount of pranoprofen and one or
more sustained-release components selected from the group
consisting of oily components, water-soluble components,
water-insoluble components, and intestinally soluble
components.
O$her objects, features and advantages of the invention
will hereinafter become more readily apparent from the
following description.
BRIEF DESCRIPTION OF 'rXE DRl~WINGS
Figure 1 is a drawing showing the relationship between
the concentration of pranoprofen in plasma an~ time
according to Test Example 1.
Figure 2 is a drawing showing the results of
dissolution test according to Test Example 2, in which is
shown the rate of dissolution of pranoprofen over time from
the sustained--release pranoprofen preparations in which
~: .
,
.. . :.
'. i , ' . ' '~; : ` 1 ;
.: - ~, .
rapid-relea~e pranoprofen and sustained-release pranoprofen
are mixed.
Figure 3 is a drawing showing the results o
dissolution test according to Test Example 2, in which is
shown the rate of dissolution of pranoprofen over time from
the sustained-release pranoprofen preparations from which
the release of pranoprofen is sustained by a matrix~forming
component.
Figure 4 is a drawing showing the results of
dissolution test according to Test Example 2, in which is
ahown khe rate of dissolution of pranoprofen over time from
the sustained-release pranoprofen preparations from which
the release of pranoprofen is sustained by a film-forming
component.
Figure 5 i~ a drawing showing the results of
dissolution test according to Test Example 2, in which are
shown the rate of dissolution of pxanoprofen over time from
the sustained=release pranoprofen preparations from which
the release of pranoprofen is su~tained by a microcapsule
comprising a film-forminy component; and the rate of
dissolution of pranoprofen over time from the sustained-
release pranoprofen preparations from which the release of
pranoprofen is sustained by matrix-forming components and
film-forming components,
'`'~: , "' :
.
.
.
DETAILED DESCRIP'rION OF THE INVENTION
AND PRE~ERRED EMBODIMENTS
In the sustained release preparation of the present
invention the sustained-release components selected from the
group consisting of oily components, water-soluble
components, water-insoluble components, and intestinally
soluble components form a matrix or film, or both, by which
the release of pranoprofen is retarded. Among the above
components, oily components, water soluble components,
water-insoluble components, and intestinally soluble
components can form a matrix; oily components, water-
insoluble components, and intestinally soluble components
can form a film. They may be used either individually or in
combination in the sustained-release composition of the
present invention.
Any oily components which can form a matrix or film and
can retard the release of pranoprofen may be used ~or the
purpose of the present invention, including, but not limited
to, oils and fats, waxes, hydrocarbons, higher fatty acid~,
higher alcohols, esters, metal salts of higher fatty acid,
and the like. Given as specific examples of oils and fat~
are vegetable oils such as cacao butter, palm oill Japan
waxr coconut oil, and the like; animal oils such as beef
tallow, lard, horse tallow, mutton tallow, and the like;
hydrogenated oils derived from fish or animal oils such as
hydxogenated fish oils, hydrogenated whale oil, hydrogenated
beef tallow, and the like; and hydrogenated oils derived
from vegetable oils such as hydrogenated rapeseed oil,
. . ~
- ~ ,
:. , , , ~
7J ~
hydrogenated castor oil, hydrogenated coconut oil,
hydrogenated soybean oil, and the like. Specific examples
of waxes include plant waxes, e.g. carnauba wax, candelilla
wax, hayberry wax, auricurry wax, espalt wax, etc.; animal
waxes, e.g. yellow wax, white wax, insect wax, spermaceti,
shellac, lanolin, etc.; and the like. Paraffin, petrolatum,
microcrystalline wax, and the like, are given a~ specific
examples o hydrocarbons. Given as specific examples of
higher fatty acids are fatty acids having 8~32 carbon atoms,
such as caprilic ac.id, undecanoic acid, lauric acid,
tridecanoic acid, myristic acid, pentadecanoic aaid,
palmitic acid, malgaric acid, stearic acid, nonadecanoic
acid, arachic acid, heneicosanoic acid, behenic acid,
tricosanoic acid, lignoceric acid, pentacosanoic acid,
cerotic acid, heptacosanoic acid, montanic acid,
nonacosanoic acid, melissic acid, hentriacontanic acid,
dotriacontanic acid, and the like. Specific examples of
higher alcohols are higher alcohols having 12-32 carbon
atoms such as lauryl alcohol, tridecyl alcohol, myristyl
alcohol, pentadecyl alcohol, cetyl alcohol, heptadecyl
alcohol, stearyl alcohol, nonadecyl alcohol, arachyl
alcohol, behenyl alcohol, carnaubic alcohol, ceryl alcohol,
corianyl alcohol, and myricyl alcohol. Specific examples of
esters are fatty acid esters, e.g. myristyl palmitate,
stearyl stearate, myristyl myristate, behenyl behenate,
c~ryl lignocerate, lacceryl cerotate, lacceryl laccerate,
etc.; glycerine fatty acid esters, e.g. glyceril
. . . .
:` ~ ~ : , : , , ;
' ,: ` ': :
.
monolaurate, glyceril monomyristate, glyceril monostearate,
glyceril monobehenate, glyceril monooleate, glyceril oleate
stearate, glyceril dilaurate, glyceril dimyristate, glyceril
distearate, glyceril trilaurate, glyceril trimyristate,
glyceril tristearate, glyceril acetylstearatet, glyceril
trihydroxystearate, etc.; and the like. Specifi.c examples
of metal salts of higher fatty acid are calcium stearate,
magnesium stearate, aluminum stearate, zinc stearate, Z1JIC
palmitate, zinc myristate, magnesium myristate, and the
like.
Preferred water-soluble polymers are those which can
form matrix and produce hydrogel in gastrointestinal kract.
Specific examples include cellulose derivatives, 2.g.,
methylcellulose, hydroxypropylcellulose, hydroxypropyl
methylcellulose, carboxymethylcellulose sodium, etc; starch
derivatives, e.g., sodium carboxymethyl starch, dextrin,
pregelatinized starch, pullulan, etc.; vinyl derivatives,
e.g., polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl
alcohol~ etc.; acrylic acid derivatives, e.g., polyacrylic
acidj sodium polyacrylate, etc.; naturally occurring
polymers and their derivatives, e.g.; acacia, tragacanth,
locust bean gum, guar-gum, casein, karaya gum, pectin,
arginic acid, agar, keratin, propylene glycol arginate,
etc.; and the like.
As water-insoluble components, polymeric compounds
which are different from common oily substances, but which
form a matrix or a film can be used. Specific examples are
. .
microcryskall.ine cellulose, ethylcellulose, aminoalkyl
methacrylate copolymer RS, cellulose acetate, polyvinyl
acetate, polyvinyl chloride, an.d the like.
As specific exampl.es of intestinally soluble
components, polymeric compounds forming a matrix or a film
and do not soluble below the pH of stomach (about pH 4) but
soluble in the pH range of 5.0-7.0, may be used. Specific
examples are methac~ylic acid copol~mer S, methacrylic acid
copolymer L, carboxymethyl ethylcellulose, purified shellac,
hydroxymethylphthalate cellulose, hydroxypropylmethyl-
cellulose phthalate, cellulose acetate phthalater
hydrox~propylmethylcellulose acetate succinate, methacrylic
acid copolymer LD, cellulose acetate trimeritate, polyvinyl
acetate phthalate, and the like.
The amounts of the above sustained-release components
in the sustained-release pranoprofen composition of the
present invention depend on the type of the preparation, the
method of preparation, and the desired sustained-release
: characteristics, and the like~ ~hen they are used as a
component for forming a matrix, an amount of 3-80% by
weight, especially 4-70~ by weight, in the total amount of
the composition is preferable, and when used as a component
for forming a film, an amount of 0.5-80% by weight,
especially 2-40% by weight, is preferable.
Any base components commonly used for conventional
pharmaceutica:L preparations, such as binders, lubricants,
disintegrators, plasticizers, dissolution modifiers,
- ~ :
.. . .
'~$'J~ .J
excipients, and the like can be added to the preparation of
the present invention.
There are no limitations as to forms of the preparation
of the present invention so long as such forms are suitable
for oral administration; it can be powders, granwles, beads,
tablets, capsules, or the like.
The sustained-release pranoprofen preparation of the
present invention can be prepared, for example, (1) by
adding sustained-release components in the form of solid,
soluti.on ox suspenæion to pranoprofen, and preparing the
mixture into any desired form according to a conventional
method; or (2) by preparing a composition of pranoprofen and
base components, followed by encapsulation of the
composition into microcapsules by using sustained-release
components or by covering of the composition with
sustained-release components by a dry or wet method.
In order to further control the release rate of
pranoprofen from the preparation prepared by the above
method, it may be further coated with one or more of oily
components, water-însoluble components, or intestinally
soluble components. Fur-thermore, it is possible to combine
two o.r more sustained-release pranoprofen preparations with
different release rates; or in order to exhibit more rapid
pharmaceutical effects after the administration, a
: preparation which is the mixture of the abvve sustained-
release pranoprofen preparation and non-sustained-release
pranoprofen preparation, or a preparation in which a
" ~ " '' ' ' :~
:. '', ~" ' '
. . . .
. . ' '' . ~
~~ 3
sustained-release pranoprofen preparation and a non-
sustained-release pranoprofen preparation are separately
layered can be used. The amount of non-sustained-release
pranoprofen to be formulated in such a preparation is
usually such that the amount of pranoprofen in such a non-
sustained-release preparation is in a range of 10-60% by
weight, and preferably 15-50% by weight/ of the total amount
of pranoprofen contained in the preparation, although thi~
proportion depends on a desired blood concentration, a
period of time during which the pha.rmaceutical effects are
required to last.
The sustained-release pranoprofen preparation thus
obtained is capable of retarding the release of pranoprofen
therefrom and maintaining its blood concentration at a
certain level for a long period of time. Dosing once or
twice a day can bring about the same effects as provided by
several time dosing of conventional preparations, thus
avoiding nui~ance of frequent dosing and the reduction of
clinical effects due to omission of dosing. The preparation
of the present invention greatly improves the treating
effects by pranoprofen by suppressing a rapid increase in
blood concentration of this drug and by safely deriving the
maximum effect of pranoprofen for a long period of time.
Other features of the invention will become apparent in
the course of the following description of the exemplary
embodiments which are given for illustration of the
invention and are not intended to be limiting thereof.
~::
.. .
.
:
EX~UPLES
Example 1
Pranoprofen 1,260.0 gm
Hydrogenated castor oil320.0 gm
Stearic acid 320.0 gm
Microcrystalline cellulose300.0 gm
Total 2,200.0 gm
Purified water (720 gm) was added to the powder of the
above components, and the mixture wais Xneaded and extruded
from a extrusion granulator to obtain rod-shaped granules.
The granules were rounded by a Marumerizer and dried at 55C
for 3 hours. Beads thus prepared were sieved to obtain
sustained-release beads (a) which passed through a 14 mesh
sieve but not a 26 mesh sieve. Sustained-release beads (a)
were blended with of the following composition and
compress-molded to prepare sustained-release tablets (A); a
tablet having a diameter of 9 mm and weighing 350 mg.
Sustained-release beads (a) 275.0 gm
Pranoprofen 67.5 gm
Microcrystalline cellulose 333.5 gm
Colloidal silicon dioxide 7.0 gm
Magnesium stearate 10.0 gm
Talc 7 0 gm
: - T~tal 700.0 gm
:
~ .
'
' .
Example 2
600 gm of sustained-release beads (a) prepared in
Example 1 were charged into a fluidized coating apparatus
and spray-coated with 1,666 gm of a coating fluid having the
following composition according to a conventional method to
obtain sustained-r~lease beads (b).
Methacrylic acid copolymers S 6.5%
Glycerine fatty acid ester 0.5%
Talc 0.2%
Ethyl alcohol 92.8%
Total 100.0%
Sustained-release beads (b) were blended with
components of the following composition and compress-molded
to prepare sustained-release tablets (B); a tablet weighing
350 mg and having a diameter of 9 mm.
Sustained-release beads (b)330.0 gm
Pranoprofen 67.5 gm
Microcrystalline cellulose278.5 gm
Colloidal silicon dioxide 7.0 gm
Magnesium stearate 10.0 gm
Talc 7.0 gm
. ~
Total 700.0 gm
Example 3
300 gm of sustained-release beads (a) prepared in
Example 1 were charged into a fluidized coating apparatus
and spray-coated with 866 gm of a coating fluid having the
11
'' '` ~ " ~
;
.
.
..
following composition accordi.ng to a conventional method to
obtain sustained-release beads (c~.
Purified shellac 4.5%
Castor oil 0.5%
Talc 0.2~
Ethyl alcohol 94.8%
. _ . . _ _ . . . .
Total 100.0%
Sustained-release beads (c) were blended with
components of the following composition and compress-molded
to prepare sustained-release tablets (C); a tablet weighing
350 mg and having a diameter of 9 mm.
Sustained-release beads (c)316.3 gm
Pranoprofen 67.5 gm
Microcrystalline cellulose292.2 gm
Colloidal silicon dioxide7.0 gm
Magnesium stearate 10.0 gm
Talc 7.0 gm
To-tal 700.0 ~m
Example 4
Sustained-release beads (a) prepared in Example 1 and
.
sustained-release beads ~b) prepared in Example 2 were
blended with components of the following composition and
compress-molded to prepare sustained~release tablets (D); a
~ tablet weighing 350 mg and having a diameter of 9 mm.
; :Sustained-release beads (a)137.5 gm
Sustained-release beads (b)165.0 gm
12
:::
,
.
:
.
~ ' I .
~ ~ ~$ ~ P~
Pranoprof~n 67.5 gm
Microcrystalline cellulose 306.0 gm
Colloidal silicon dioxide 7.0 gm
Magnesium stearate 10.0 gm
Talc 7.0 gm
. . _ ~ . . . _ ~ . _ _ _
Total 700.0 gm
Example 5
150 gm of sustained-release beads (a) prepared in
Example 1 were charged into CF-granulator (trademark,
manufactured by ~reund International Ltd.~ and spray-coated
with 658.5 gm of a coating fluid having the following
composition according to a conventional method to obtain
sustained-release beads (d).
Pranoprofen 4.0%
Hydroxypropyl cellulose 1.0%
Talc 0.2%
~thyl alcohol 94.8%
Total 100.0%
Example 6
Pranoprofen 360.0 gm
Microcrystalline cellulo~e 632.0 gm
,
; Total 992.0 gm
: Purified water ~753 gm) was added to the powder of the
above components, and the mixture was kneaded and extruded
from a extru~i.on granulator to obtain rod-shaped granules.
The granules were rounded by a Marumerizer and dried at 55C
~: 13
: . . ..... . .
., . , ~.
.:
,c 1"i 't
for 3 hours. Beads thus prepared were sieved to obtain
sustained-release beads (e) which passed through a 14 mesh
sieve but not a 26 mesh sieve.
Example 7
Pranoprofen 900.0 gm
Microcrystalline cellulose 260.0 gm
Total 1160.0 gm
A solution of hydroxypropylmethyl cellulosa (45 gm)
dissolv~d in 405 gm of purified water was added to the
powder of the above components, and the mixture was kneaded
and extruded from a extrusion granulator to obtain rod-
shaped granules. The granules were rounded by a Marumerizer
and dried at 55C for 5 hours. Beads thus prepared were
sieved to obtain sustained-release beads (f) which passed
through a 14 mesh sieve but not a 26 mesh sieve.
Example 8
300 gm of sustained-release beads (f) prepared in
Example 7 were charged into a fluidized coating apparatus
and spray-coated with 71.6 gm of a coating fluid having the
following composition according to a conventional method to
obtain sustained-release beads (g).
Aminoalkyl methacrylate copolymer RS 14.0%
Triethyl citrate 4.2%
Colloidal silicon dioxide 2.8~
Purified water 79.0%
Total 100.0
14
.
' ` ' :
.` ; ,, ' ' '
'
Example 9
- Pranopr~fen 630.0 gm
Hydroyenated castor oil 400.0 gm
~ . .. . _ _ _
Total 1030.0 gm
A solution of hydroxypropylmethyl cellulose (50 gm)
dissolved in 450 gm of purified water was added to the
pow~er of the above components, and the mix-ture was kneaded
and extruded from a extrusion granulator to obtain rod-
shaped granules. The granules were rounded by a Marumeriæer
and dried at 55C for 3 hours. Beads thus prepared were
sieved to obtain sustained-release beads (h~ which passed
through a 14 mesh sieve but no-t a 26 mesh sieve.
Example 10
Pranoprofen 112.5 gm
Methylcellulose 420.0 gm
Lactose 150.0 gm
Colloidal silicon dioxide7.0 gm
Magnesium stearate 3.5 gm
Talc 7.0 gm
Total 700.0 gm
The powder mixture of the above composition was
compress-molded to prepare sustained-release tablets (E~; a
tablet weighing 350 mg and having a diameter of 9 mm.
Example 11
Pranoprofen 640.0 gm
Corn starch 240.0 g~
. .
Total 880.0 gm
, ,; ;
~;
c~
The above powder mixture was pulveri~ed and granulated
by a rotating granulator using 350 gm of 24-32 mesh non-
pareil seeds as a core while applying a solution of 62.5 gm
of purified shellac dissolved in 1,187.5 gm of ethyl
alcohol. The beads thus obtain~ad were dried at 55C for 2
hours and were sieved to obtain sustained-release beads (i)
which passed through a 14 mesh .sieve but not a 26 mesh
sieve.
Example 12
Pranoprofen 2364.0 gm
Corn starch 1260.0 gm
Total 3624.0 gm
The above powder mixture was granulated by a rotating
granulator using 1,260 gm of 28-35 mesh purified sucrose as
a core while applying a solution of lOS gm of hydroxypropyl
cellulose dissolved in l,99S gm of 50% ethyl alcohol. The
beads thus obtained were dried at 55C for 2 hours and
sieved to obtain non-coated beads (j) which passed through a
14 mesh ~ieve but not a 26 mesh sieve.
300 gm of beads (j) thus prepared were charged into a
fluidized coating apparatus and spray-coated with 1,042 gm
of a coating fluid having the following composition
according to a conventional method to obtain sustained-
release beads (k).
Methacrylic acid copolymer h6.5~
Glycerine fatty acid ester 0.5%
Talc 0.2%
Ethyl alcohol 32.8%
Total 100.0%
16
~ .
,
' , '
sj
Example 13
300 gm of beads (j) prepared i.n Example 12 were chargedinto a fluidized coating apparatus and spray-coated with
1,042 gm of a coating fluid having the following composition
accordiny to a conventional method to obtain sustained-
release beads (m).
Methacrylic acid copolymers S 6.5%
Glycerine fatty acid ester 0.5
Talc 0.2%
Ethyl alcohol 92.8%
Total 100.0%
Examp~e 14
300 gm of beads (j) prepared in Example 12 were chargedinto a fluidized coating apparatus and spray-coated with
1,210 gm of a coating fluid having the following composition
according to a conventional method to obtain sustained-
release beads (n).
Hydroxypropylmethylcellulose phthalate 6.0%
~alc 0.2%
Purified water 18.8%
Ethyl alcohol 75.0
Total 100.0
Example 15
: 500 gm of beads (~) prepared in Example 12 were charged
into a fluidized coating apparatus and spray-coated with 375
gm of a coating fluid having the following composition
according to a conventional method to obtain sustained-
~7
.
,. . , , :
, ~
.. . .
?J ~.3 ~
release beads (p).
White wax 10.0%
Glyceril monostearate 10.0%
Talc 30,0
Isopropyl alcohol 50.0
Total 100.0%
Example 16
400 gm of beads (j) prepared in Example 12 were charged
into a fluidized coating apparatus and spray-coated with
1,800 gm of a coating fluid having the following compo~ition
according to a conventional method to obtain sustained-
release beads (q).
Aminoalkyl methacrylate copolymer RS 3.2%
Glycerine fatty acid ester 0.3~
Talc o~s%
Ethyl alcohol 94.0%
_ _ _ . _ _ _ . . _
Total 100.0
Example 17
300 gm of beads (;) prepared in Example 12 were charged
into a fluidized coating apparatus and spray-coated with
1,317 gm of a coating fluid having the following composition
according to a conventional method to obtain sustained-
~ release beads (r).
; Aminoalkyl methacrylate copolymer RS 2.2%
Polyvinylpyrrolidone 1.1%
Glycerine fatty acid ester0.3~
Talc 0,5%
', ' ~ . ~ '
. .
,
Ethyl alcohol 95.9~
_ _ ~ _ . _ . ~ .. . . _ _ _
Total 100.0%
Sustained-release beads (r) were mixed with following
o~her components and compress-molded to prepare sustained-
release tablets (F); two tablets weighing 400 mg and each
tablet having a diameter of 8 mm.
Sustained-release beads (r) 209.4 gm
Micxocrystalline cellulose 185~6 gm
Colloidal silicon dioxide 4.0 gm
Magnesium stearate 1.O ~m
~: .7 .: .__ _ . ____ . _ _ ._ _ _ . _ ._. _
Total 400.0 gm
Example 18
300 gm of beads (j) prepared in Example 12 were charged
into a fluidized coating apparatus and spray-coated with
1,317 gm of a coating fluid having the following composition
according to a conventional method to obtain sustained-
release beads (s).
~minoalkyl methacrylate copolymer RS 1.1%
Methacrylic acid copolymers S 1.1%
Hydroxypropyl cellulose 1.1%
Glycerine fatty acid ester 0.3%
Talc o.s%
Ethyl alcohol 95.9%
.
Total 100.0%
Sustained-release beads (s) were mixed with the
following other components and compress-molded to prepare
sustained-release tablets ~G); two tablets weighing 400
19
.
. ~ -
. .
- ~ ~
~d/~
mg and each tablet having a diameter of 8 mm.
Su~tained-release beads (s) 209.4 gm
Microcrystalline cellulose 185.6 gm
Colloidal silicon dioxide 4.0 gm
Magnesium stearate 1.O gm
. _
Total 400.0 gm
Example 1~
300 gm of beads ti) prepared in Example 12 were charged
into a fluidized coating apparatu~ and spray-coated with 143
gm of a coating ~luid having the following composition
according to a conventional method to obtain sustained-
release beads (t).
Ethylcellulose 1.5%
Polyvinylpyrrolidone 0.5%
Talc 0.1%
Ethyl alcohol 97.9%
~ _ _ .
Total 100.0%
Example 20
500 gm of beads (p) prepared in Example 15 were charged
~; into ~ fluidized coating apparatus and spray-coated with
1,736 sm of a coating fluid having the following composition
according to a conventional method to ohtain sustained~
release beads lu).
Methacrylic acid copolymers S 6.5%
Glycerine fatty acid ester 0.5%
Talc o.
Ethyl alcohol 92.8%
Total 100.0
.
': ~
! ~
Example 21
Pranoprofen 33.9 gm
Polyethylene glycol 60010.2 gm
Ethylcellulose 101.6 gm
Total 145.7 gm
The above components were dissolved into 2,850 qm of
ethyl alcohol. Colloidal silicon dioxide (4.4 gm) was
dispersed in the solution thus obtained. The mixtuxe was
spray-dried according to a conventional method to obtain
sustained-release powder (v). The powder (v) was cornpress-
molded together with other components shown below to prepare
sustained-release tablets (H); two tablets weighing 517 mg
and a tablet having a diameter of 8 mm.
Sustained-release powder (v)150.1 gm
Croscarmellose sodium 3.5 gm
Colloidal silicon dioxide0.8 gm
Magnesi~m stearate 0.7 gm
Talc 0.7 gm
_
Total 155.8 gm
Test Example 1
Two (2) tablets (pranoprofen content: 225 mg), each
from sustained-release tablets A, B, and C prepared in
Examples 1-3, and a commercially available conventional
capsule ~pranoprofen content: 75 mg) were administered to
healthy male adults (each sample to 3 persons) together with
180 ml of water 30 minutes after meal. The concentration of
21
.
. .
.....
3 rJI
pranoprofen in plasma was measured over time by high
performance liquid chromatography. The results are shown in
Figure 1, which demonstrates that sustained-release tablets
A-C of the present invention maintained a certain level of
pranoprofen plasma concentration for a long period of time
without lowering its bioavailability.
Test Ex~mple 2
Dissolution o~ pranoprofen from sustained-release
pranoprofen preparations of the present invention and from a
commercially available conventional capsule was measured by
the rotation paddle method tThe Pharmacopeia of Japan, 11th
edition) using a buffer test solution of pH 6.8. ~he
results are shown in Figures 2-5, which demonstrates the
controlled release rate of pranoprofen from the preparation
of the present invention as compared with the dissolution
from the conventional available capsule.
*****************************************
Obviously~ numerous modifications and variations of the
present invention are possible in light of the above
teachings. It is therefore to be understood that within the
scope of the appended claims, the invention may be practiced
otherwise than as specifically described herein.
,
.
~ . ~
